Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accumulated Expenses (2016 - 2025)

Guided Therapeutics' Accumulated Expenses history spans 16 years, with the latest figure at $952000.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 3.14% year-over-year to $952000.0; the TTM value through Sep 2025 reached $952000.0, up 3.14%, while the annual FY2024 figure was $1.0 million, 5.34% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $952000.0 at Guided Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.9 million in Q1 2021 and bottomed at $6000.0 in Q1 2025.
  • The 5-year median for Accumulated Expenses is $923000.0 (2024), against an average of $892155.0.
  • The largest annual shift saw Accumulated Expenses skyrocketed 3568.18% in 2023 before it tumbled 99.23% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $49000.0 in 2021, then surged by 2444.9% to $1.2 million in 2022, then fell by 14.35% to $1.1 million in 2023, then decreased by 5.34% to $1.0 million in 2024, then dropped by 5.84% to $952000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Accumulated Expenses are $952000.0 (Q3 2025), $1.1 million (Q2 2025), and $6000.0 (Q1 2025).